Replies to post #89428 on Cytodyn Inc (CYDY)

[SaraLovesYou]

For our purposes, Tocilizumab is a non-starter since it's an IL-6 inhibitor only. Leronlimab targets IL-6 and the CCL5 (Rantes)/CCR5 pathway.
__________________________________

Borel Fields Tuesday, 06/30/20 11:41:01 PM
Re: bobshmob post# 89359 0
Post # of 89432
Some good outcomes on tocilizumab, but not randomized, as paragraph 2 of the Lancet paper notes: "a non-randomly selected subset of patients also received tocilizumab."

No question, the list of possible storm-treating drugs is narrowing to leronlimab (first with randomized trial results), tocilizumab and lenzilumab. And everyone understands we need storm-treating drugs.

[bobshmob]

Egad. I missed the "non" in "non-randomized". Although low, their p-values are garbage without a good sample.

Still waiting for a good sample for tocilizumab. And it looks like we won't have one until September for lenzilumab. But any day now for leronlimab.